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Concern is growing among many
university life scientists that the
inevitably increasing reliance on
commercial funding for research may
be jeopardising traditional academic
standards. Governments faced with
burgeoning science budgets are
increasingly wooing industrial funds
to help maintain their researchers. In
Britain, the government has made
particular efforts to bring together
public and private funds within the
university sector. But some believe
that it is now time to rethink the
relationship. “The problems of
industrial funding of research are
seen as a public issue as the
importance of life sciences
increasingly impinges on ordinary
life,” says Gill Evans, public policy
officer for Britain’s Campaign for
Academic Freedom and Standards
(CAFAS). Many researchers believe
that the issues now need to be
addressed.
One of the key issues
heightening concern is the
publication of the draft human
genome sequence and the inevitable
commercial interest in exploiting its
content. The Association of the
British Pharmaceutical Industry has
recently published a report:
Evolution and Revolution: How
genomics will change health care which
flags up just how keen
pharmaceutical companies are to
exploit the new information and how
crucial commercial funding will be.
But academics are increasingly
concerned that they may be the
losers in the new relationship with
industry. “It’s often small things like
the pressure to publish now rather
than later, or not to pursue some
slightly offbeat piece of research,”
says Evans.
A recent meeting organised by
CAFAS, highlighted some of the key
problems. Nancy Olivieri, a
haematologist at the Toronto
University’s Hospital for Sick
Children, told of how her research
led to difficulties. With public
funding, she had been researching
oral methods of chelation of iron
which otherwise can lead to a fatal
build up in the blood of thalassemia
patients.
The problems of industrial
funding of research are seen as a
public issue and the importance
of life science increasingly
impinging on ordinary life
With a promising compound, she
published her initial results. Further
public funding was then withheld as
the work was considered to be of
commercial potential. But when she
won commercial funding but found
the compound failing to live up to its
early promise, she fell into
considerable difficulty with the
company and her university. 
She is particularly concerned
about the general validity and
disinterestedness of drug trials, given
that academics are increasingly
promoted for pursuing company
agendas.  As the Canadian MRC did
not take up funding of her work
when the company withdrew, she
wonders who has an incentive to
pursue findings that drugs lack
efficacy.
David Weatherall, of Oxford
University’s Institute of Molecular
Medicine, spoke about the spiralling
costs of research and how this makes
company involvement inevitable.
But he is concerned by the way an
increased reliance on industrial
sponsors leads to conflicts of interest,
bias, contractual pressures and even
ghost writing of papers for industrial
colleagues. He called for changes to
reduce the pressure for short-term
gain, rationalization of patent law for
biologicals, funding to give scientists
long-term careers in clinical science,
protection for scientists and, should
any dispute arise, external,
disinterested review.
There was widespread concern at
the meeting that current measures to
handle potential conflicts of interest
were inadequate. While some
funding agencies, universities and
journals require information about
commercial interests, many believe a
much larger-scale process is needed.
“Science is international and
measures are needed to reflect this,”
says Evans. But there was also
concern not to develop a ‘policing
and punishing’ regime. Many
believe that an approach that
educates researchers about the issues
could lead to a situation where
someone in every laboratory knows
what should and should not be done
in pursuit of these concerns, she
says.
A new innovation in the US to
help tackle these issues is a website
listing researchers and their funding
interests. The website reveals the
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names of more than 1,100 university
researchers and dozens of non-profit
organizations whose work is being
underwritten by the private sector.
The disclosure follows reports that
scientists have been pressured to
tailor research for the sake of
sponsoring corporations and that
journal editors have not disclosed
potential conflicts.
The site was launched by the
non-profit Center for Science in the
Public Interest based in Washington
DC. Director Michael Jacobsen said:
“Corporations increasingly are
funding academic scientists to
conduct research… and provide
advice. Too frequently, neither the
scientists or the corporations disclose
that.”
Concern about such conflicts of
interest has escalated in the past two
years. The New England Journal of
Medicine admitted that it had
published at least 19 articles by
authors who had financial
connections to drug companies
involved with the subject of their
work. Despite this, a study released
last month found that of 61,000
articles in 181 journals, just 0.5%
disclosed potential conflicts.
Sheldon Krimsky, a professor of
environmental policy at Tufts
University, who studies such
conflicts, said that because there was
no law requiring the disclosure of
financial conflicts of interest among
scientists, the site ‘provides a
valuable way for citizens and the
media to gain a better understanding
of an important source of bias.’
Organizers of the site said they
wanted potential conflicts disclosed,
particularly by journalists who used
academics as sources. Ronald Collins,
director of the project said: “All too
often reporters quoted scientists
without providing the public with
information about their ties to
industry.” 
“What people want is openness
and a situation where researchers can
freely express their doubts,” says
Evans.
